logo
Share SHARE
FONT-SIZE Plus   Neg

CIT To Redeem $500 Mln Of 7% Series C Senior Unsecured Notes Maturing In 2017

CIT Group Inc. (CITGQ.PK,CIT) said it will redeem $500 million of its 7% Series C Senior Unsecured Notes maturing in 2017. Following the redemption, around $3.6 billion principal amount of the Notes maturing in 2017 and approximately $3.1 billion principal amount of the Notes maturing in 2016 will remain outstanding.

"We will continue to eliminate or refinance our remaining high-cost debt as we work to further improve our funding profile," said John Thain, Chairman and Chief Executive Officer.

Including the redemption announced today, as well as the approximately $1.6 billion redemption of 7% Series C Senior Unsecured Notes maturing in 2015, CIT announced on March 15, 2012, that it will have eliminated or refinanced approximately $24 billion of high cost debt since the beginning of 2010.

The company has issued a redemption notice for the Notes to the trustee and plans to complete the redemption announced today on May 2, 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Snack and beverage giant Pepsico Inc. reported Thursday significantly higher profit in its third quarter, reflecting the absence of last year's hefty Venezuelan impairment charges, despite weak revenues. Core earnings and revenues beat market estimates. Further, the company lifted its fiscal 2016 forecast on its performance and outlook for the fourth quarter. Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects.
comments powered by Disqus
Follow RTT